Free Trial
NASDAQ:KRRO

Korro Bio Q1 2024 Earnings Report

Korro Bio logo
$13.90 +0.44 (+3.27%)
Closing price 04/17/2025 04:00 PM Eastern
Extended Trading
$13.79 -0.11 (-0.79%)
As of 04/17/2025 06:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Korro Bio EPS Results

Actual EPS
-$2.44
Consensus EPS
-$2.36
Beat/Miss
Missed by -$0.08
One Year Ago EPS
N/A

Korro Bio Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Korro Bio Announcement Details

Quarter
Q1 2024
Time
N/A
Conference Call Date
Tuesday, May 14, 2024
Conference Call Time
4:00PM ET

Upcoming Earnings

Korro Bio's Q1 2025 earnings is scheduled for Tuesday, May 13, 2025, with a conference call scheduled at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Korro Bio Earnings Headlines

Chardan Capital Initiates Coverage on Korro Bio (NASDAQ:KRRO)
Chardan Capital Initiates a Buy Rating on Korro Bio (KRRO)
Trump to unlock 15-figure fortune for America (May 3rd) ?
We were shown this map by former Presidential Advisor, Jim Rickards, one of the most politically connected men in America. Rickards has spent his fifty-year career in the innermost circles of the U.S. government and banking. And he believes Trump could soon release this frozen asset to the public.
Korro Bio initiated with a Buy at Chardan
Brokerages Set Korro Bio, Inc. (NASDAQ:KRRO) Target Price at $136.33
See More Korro Bio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Korro Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Korro Bio and other key companies, straight to your email.

About Korro Bio

Korro Bio (NASDAQ:KRRO), a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, OPERA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe alcohol-associated hepatitis, and other subsets of pain. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

View Korro Bio Profile

More Earnings Resources from MarketBeat